CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients
DOI 10.1055/s-0033-1352747
Bibliografische Angaben
Nachweis in CareLit
Autor:innenP Buggisch, M Buti, K Agarwal, YJ Horsmans, W Sievert, E Janczewska, RS Brown, C Hezode, M Rizzetto, R Parana, S De Meyer, D Luo, J Witek, S Zeuzem
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: The ADVANCE study showed that telaprevir (TVR, T) every 8 hours (q8h) combined with peginterferon alfa-2a (P) and ribavirin (R) had superior efficacy to PR alone. Reported here are results from OPTIMIZE, a Phase III, randomized, open-label, international, non-inferiority study comparing twice daily (bid) vs. q8h TVR (NCT01241760). Methods: Treatment-naive patients with genotype 1 (G1) HCV infection were random…
Zitieren
Zitierempfehlung
P Buggisch, M Buti, K Agarwal, YJ Horsmans, W Sievert, E Janczewska, RS Brown, C Hezode, M Rizzetto, R Parana, S De Meyer, D Luo, J Witek, S Zeuzem (2013) OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0033-1352747
Mit CareLit weiterarbeiten